Transforming Traditional Medical Affairs to Launch the Next Generation of Breakthrough Gene Therapy Products
The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients.
Industry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies.
Join this definitive, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before.
This virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement, discussion, and Q&A’s in order for you to get the best value from this meeting.
Access the official agenda for more information.
Previous Gene Therapy attendees have said:
“Inspiring virtual meeting allowing efficient learning about the most recent advances in gene therapy immunogenicity while still having interactions with peers.”
Cornelia Ciorciaro, Director - Safety Science Group Medical, Roche
“It was great to have a conference focused on analytical challenges for testing immune markers and modulating immune responses to gene therapies.”
Michele Stone, Vice President - Translational Development, Kriya Therapeutics
“I learned a lot about the what, who & how of the AAV gene therapy field.”
Robert J Kubiak, Clinical Pharmacologist, AstraZeneca
When you look inside your copy of the agenda, you will see 3 different session types:
Offering you the chance to hear the most admired medical affairs professionals from the gene therapy world share the stories and case studies of what they’ve done to solve their more pressing challenges.
Providing you with the unique opportunity to have your burning questions answered in a virtual room filled with your industry peers, and move beyond the “what” and the “why” to get to the “how”.
Designed to help you work with your team to set a clear, bespoke action plan of what you are going to change when you get back to your organization to ensure you see a fast ROI.
Medical Affairs Professional Society
MAPS is the premier non-profit global Medical Affairs organization FOR Medical Aﬀairs professionals BY Medical Affairs professionals across all diﬀerent levels of experience and speciality to engage, empower and educate. Together with approximately 4,000 Medical Affairs members from over 200 companies globally, MAPS is transforming the Medical Affairs profession to increase its value to patients, HCPs and other decision-makers. A key objective of MAPS is to provide guidance, best practices, and networking within 12 focus areas, including Rare Disease & Gene Therapy. Join the conversation by becoming a member today!